Drug intelligence / Profile preview

AZD2551

Development stage: Unknown
Lead developer: AstraZeneca
Modality: Small Molecules
Administration: Oral

Overview

AZD2551 is a small molecule drug developed by AstraZeneca. It was investigated as an oral peptide hydrolase (peptidase) inhibitor, with the aim of modulating peptidase activity in humans. The drug underwent Phase 1 clinical trials to assess its safety, tolerability, and pharmacokinetics in healthy male volunteers. The trial involved single ascending oral doses of AZD2551 but did not progress beyond early-stage development and has since been discontinued[1][2][9]. No specific therapeutic indication or disease target was advanced publicly before discontinuation.

Beyond the preview

Go deeper on AZD2551.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AZD2551.

Explore the full profile